Analysis: New Novartis heart failure med has consumers talking

Novartis ($NVS) has been talking up the potential of its brand-new heart failure therapy, Entresto, noting that it could be the company's biggest launch ever. And consumers are taking note. According to healthcare insights company Treato, the therapy has seen a 1400% increase in online consumer conversation since it won its FDA green light. More than 30% of the 128,000 conversations Treato tracked mentioned hospitalizations, too--a sign that consumers understand the impact the drug could have. More from FiercePharmaMarketing